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Summary 
We have generated transgenic mice that express the immunoglobulin (Ig)M heavy chain and 
K light chain genes coding for a human IgM rheumatoid factor (R.F), Les. Transgenic B cells 
expressing human IgM KF show striking similarities  to their counterparts in normal humans. 
They comprise a significant proportion of the adult B cell population, but secrete only low levels 
of RF into the serum. The RF transgene-expressing B cells localize to primary B cell follicles 
and the mantle zone regions of secondary follicles in the spleen. Using these mice we have been 
able to show that one of the central functions of normal ILF-expressing B cells may be to act 
as highIy etiident antigen-presenting cells for low concentrations of immune-complexed  antigen. 
High levels of secretion of IgM RF can not be induced under normal circumstances,  although 
RF-expressing B calls proliferate well in vitro to both aggregated human IgG and anti-human 
IgM antibodies.  However, these mice are not intrinsically secretion deficient.  By crossing the 
RF transgenic mice with the autoimmune MRL/Ipr background, we find a dramatic increase, 
>200-fold, in levels of serum RE The results strongly suggest that a major function of normal 
resting 1LF B cells is unrelated to antibody secretion.  Rather, the RF B cells in the follicles may 
play a role in antigen presentation and regulation of immune  responses to antibody-bound nonself-, 
and possibly stir-antigens.  This physiologic role ofRF B ceils may be disrupted in RF-associated 
autoimmune disease. 
l~ 
eumatoid arthritis (RA) t is a chronic inflammatory au- 
toimmune disease that primarily affects the joints. It 
is characterized by the presence of high titers of anti-IgG an- 
tibodies (rheumatoid factors [RFs]). However, IgM RFs also 
can occur in patients with lymphoproliferative disease, and 
in normal individuals. These "natural" autoantibodies derive 
from a small set of conserved heavy and light chain variable 
region genes, that can encode RF in the absence of somatic 
mutation and are selectively rearranged early in fetal devel- 
opment (1-5). 
Igs serve two major physiologic functions. The secreted 
antibodies of plasma cells play a critical role in the effector 
phase of the immune response. Surface-bound antibodies on 
B cells focus and internalize antigen and therefore play a role 
I Abbreviations used in thispaper: CLL, chronic lymphocytic leukemia; RA, 
rheumatoid arthritis; RF, rheumatoid factor;  TT, tetanus toxoid. 
in the afferent arm of the immune response. Whether or not 
these functions are always fulfilled by the same set of B ceLls 
is not dear. 
It is thought that IgM RFs amplify the early, low affinity, 
polydonal immune response to bacterial antigens by increasing 
the avidity of antigen-bound IgG, and the fixation of com- 
plement. However, recent observations suggest that a major 
physiologic function of IgM tLF antibodies is in the cell-bound 
as opposed to the soluble form. Lymphocytes bearing cell 
surface RF constitute a significant proportion of adult B lym- 
phocytes (3), although under normal circumstances there are 
only low levels of circulating autoantibody. RF precursors 
are particularly abundant in the mantle zones of lymph nodes 
and tonsils of normal individuals who lack this autoantibody 
in their sera (6). A number of investigators have shown B 
cells to be very effective APCs, using their Ig receptor to 
capture small amounts of their specific antigen. In this way 
they are able to present antigen at 1,000-fold lower concen- 
trations than monocytes and macrophages, suggesting that 
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tion of antigen is low (7-12). Recent experiments (13) using 
an R_r,-expressing EBV-transformed B lymphoblastoid cell line 
showed that these cells were highly efficient at presenting 
low concentrations of specific antigen to halter T cells provided 
that the antigen was present in the form of an immune com- 
plex with  human IgG.  Presumably, the activated 1LF-ex- 
pressing B cells bound the IgG-antigen complexes and inter- 
nalized  them  for  processing  and  presentation.  However, 
EBV-transformed lines do not necessarily reproduce the char- 
acteristics of normal ILF-expressing B cells in vivo. The EBV- 
transformed cells divide rapidly and constitutivdy express high 
levds of the costimulatory molecules that promote T cell ac- 
tivation. Compared with stimulated B lyraphobhsts, resting 
B cells have been reported to inefficiently present antigen to 
T  cells (14-17)  and may induce T  cell anergy (18). 
To analyze the normal immune function of  B ceils expressing 
IgM RF requires large and uniform populations of RF-positive 
B cells that have developed in the presence or absence of IgG. 
However, cells expressing mouse IgM ILF normally exist in 
the presence of their target autoantigen. In addition, a mu- 
rine counterpart of the human, low affinity IgM RFs that 
show regulated expression and tissue distribution has not been 
isolated. The use of a human IgM R~ transgene in mice avoids 
these problems. Low affinity, germline-encoded autoantibodies 
are characteristically polyspedfic, reacting with a variety of 
autoantigens and potentially crossreacting with mouse I8  G. 
The Les IgM ILF derives from a patient with atypical chronic 
lymphocytic leukemia (CLL; 19-21). The Les ~  genes show 
a number of point mutation differences from germline and 
encode a protein that does not crossreact detectably  with mouse 
IgG. 
Here, we have analyzed the localization and function of 
transgenic B cells bearing the Les human IgM RF. We find 
that the transgenic B cells accumulate in primary B cell fol- 
licles and the mantle zones of secondary follicles, and display 
the antigen-presenting functions that have been postulated 
for RF B cells in normal humans. The results provide fur- 
ther support for the concept that RF B cells may regulate 
the afferent arm of the immune response to antibody-com- 
plexed self- and nonself-antigens. 
Materiah and Methods 
DNA Constructs.  The rearranged Ig heavy and light chain genes 
were isolated from the DNA of CLL cells that expressed the Las 
ILl: (19-21). After initial cloning into )~ Dash (Stratagene, La  Jolla, 
CA), a D-kb SalI fragment containing the VkIIIa (Vk328) gene 
and Ck C region, 3.1 kb of 5' sequences, and 5.0 kb of 3' sequences 
was suboloned into pUC18. A 15-kb BamHI fragment containing 
the VhIV gene and C~t C region together with 0.6 kb of 5' se- 
quences and 0.4 kb of 3' sequences  was subcloned into pSVG-gpt. 
HindIII linkers were added to a 0.8-kb EcoRI fragment containing 
the murine Ig heavy chain enhancer, and this fragment was cloned 
into the HindIII site on the heavy chain plasmid between the V 
and C regions 3' of the human enhancer. 
Creation ofTransgenic Mic~  Heavy and light chain genes coding 
for the human IgM RF were excised  from vector sequences  by SalI 
digestion. The inserts were purified on a 10-50% sucrose density 
gradient followed by extensive dialysis against 5 mM Tris, 0,1 mM 
EDTA, pH 7.5, buffer. For microinjection, the concentration of 
the fragment was adjusted to 2 ~g/ml total DNA containing equi- 
molar concentrations of the heavy and light chain constructs. Ova 
used for microinjection were derived from matings of (C57B1/6 
x  SJL/J)F1 mice. Founder lines were then maintained by back- 
cross mating with C57B1/6 or MtLL/Ipr strains (The Jackson Lab- 
oratory, Bar Harbor, ME). 
ELISA.  Positive  progeny of transgenic matings were identified 
by measuring the level  of human IgM I~ in the serum of 4-5-wk- 
old mice. Plates were coated with human IgG (Cappel Laborato- 
ries, Durham, NC) at 10/~g/ml,  and binding of serial dilutions 
of  mouse  serum  was  determined  by  sequential  addition  of 
anti-human IgM biotin (Accurate Scientific,  Co., Westbury, NY), 
streptavidin-peroxidase  (Kirkegaard & Perry Laboratories, Gaithers- 
burg, MD), and peroxidase substrate (KPL). Absorbance was mea- 
sured at 450 nm. Levels  of expression were determined by compar- 
ison with a standard curve of binding by purified Les IgM ILF. 
Levels of IgM KF in superuatants from LPS-stimulated cultures 
were determined in a similar manner. Levels  of mouse Ig in serum 
and culture supernatants were determined by coating plates with 
affinity-purified goat  anti-mouse 18  (KPL) and  detected with 
affinity-purified goat  anti-mouse Ig-biotin  (Jackson Immuno- 
research, West Grove, PA). 
Fluorescence  Analysis.  Spleen  cells for fluorescence  analysis were 
separated on Lympholyte M gradients (Accurate Scientific Co.). 
Cell phenotype was determined using the following reagents: goat 
anti-human IgM-FITC (Jackson Immunoresearch); anti-B220-PE 
(Pharmingen, San Diego, CA); anti-mouse IgD-PE (Pharmingen); 
anti-mouse tc-PE (Fisher  Scientific  Co., Httsburgh, PA); anti-mouse 
CD5-PE (Boehringer Mannheim Biochemicals, Indianapolis, IN); 
goat anti-human g-biotin (Sigma Chemical Co., St. Louis, MO); 
goat  anti-mouse IgM-biotin  (Jackson Immunoresearch);  goat 
anti-mouse IgG-biotin  (Kirkegaard & Perry Laboratories); rat 
anti-mouse CD4-biotin  (YTA3.1); rat anti-mouse CD8-biotin; 
streptavidin-PE (Molecular Probes, Eugene, OIL); and streptavidin- 
FITC (Molecular  Probes), and analyzed  on a FACScan  |  flow cytom- 
eter (Becton Dickinson & Co., San Jose, CA). 
Imraunohistochemistry.  Tissues  were snap frozen in optimal cut- 
ting temperature medium (Miles Laboratories, Inc., NaperviUe,  IL). 
4-/zm sections were prepared from the tissue blocks and stained 
with  affinity-purified goat  anti-human  IgM-biotin  (Accurate 
Scientific Co.), a~nity-purified goat anti-human g-biotin (Sigma 
Chemical Co.), avidin-D HtLP (Vector Laboratories, Burlingame, 
CA), and affinity-purified goat anti-mouse Ig-peroxidase (Boeh- 
ringer Mannheim). Briefly, 100/zl of medium or an optimal dilu- 
tion of the biotinylated reagents was added to each slide and in- 
cubated for 60 rain at room temperature. Slides were then washed 
with PBS (pH 7.2) before adding 100/zl of either anti-mouse Ig 
coupled to peroxidase or avidin D coupled to horseradish peroxi- 
dase for a further 60 rain. After washing the slides with PBS, the 
bound peroxidase was detected by incubation  with 3-amino-9- 
ethylcarbazole (Sigma Chemical Co.) at 0.4 mg/ml in 0.015% 
hydrogen peroxide in 0.1 M sodium acetate (pH 5.2) for ,u20 rain. 
Washed slides were then stained with Mayer's hematoxylin for 2 
rain before mounting. 
Generation of RF-secreting Hybridomas.  Spleens  were removed 
from AB29 transgenic mice and then teased apart in serum-free 
IMDM (Irvine Sdentific, Santa Aria, CA).  10  s spleen cells were 
combined with 6  x  107 NSO cells (kind gift of Dr. H. Wald- 
mann,  University  of Cambridge,  UK),  washed in  serum-free 
medium,  and then pelleted. 0.8 ml of polyethylene glycol 1500 
(Boehringer Mannheim) was added slowly to the pellet while stir- 
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washed,  and then plated out in four 24-well plates at 1 m)/well 
in IMDM  +  10% FCS. After 24 and 48 h, the wells were fed 
with medium supplemented with HAT (hypoxanthine, thymidine, 
aminopterin)  (Sigma Chemical Co.). Culture supematants  were 
tested at days 14-21 after fusion for the presence of human IgM 
RF. Positive  wells were then cloned and positive hybridomas selected. 
T Cell Proliferation Assay.  C57/B16 mice were immunized  at 
the base of the taft with 100/~g tetanus  toxoid in CFA (Sigma 
Chemical  Co.).  10 d later draining  lymph nodes were removed, 
teased apart, and used as a source oft helper cells. After washing, 
the cells were resuspended  at 6  x  106/ral in complete  Clicks 
(Clicks/Eagle's Hanks amino acids [Irvine Scientific] with the ad- 
dition of antibiotics, 10 mM Hepes, 50/~M 2-ME, and 10% heat- 
inactivated FCS). Spleen cells were removed from transgenic mice, 
nontransgenic  littermates, or C57/B16 control mice, teased apart, 
and resuspended at 6  x  106/rrd. After receiving 1,000 tad, these 
cells were used as a source of APC. 3  x  10  s lymph node cells and 
3  x  10  s APC were added to each well in a total volume of 100 
/~1. Wells contained either tetanus toxoid alone or preformed im- 
mune complexes of tetanus  toxoid and human IgG anti-tetanus 
toxoid (Hypertet, Cutter Biological, West Haven, CT) in a total 
volume of 100/d. Immune complexes were preformed by incuba- 
tion for 2 h at 37~  All tests were performed in triplicate. After 
3 d,  1/~Ci of [3I-I]thymidine (Tdr) was added per well and the 
assay harvested after a further 18 h using a cell harvester (PHD; 
Cambridge  Technology Inc., Watertown,  MA). [3I-I]Tdr incorpo- 
ration  was measured using a/5 scintillation counter. 
B Cell Proliferation  Assays.  Spleens  were removed from trans- 
genie mice, nontransgenic  littermates,  or control C57/B16 mice 
and  teased apart.  Cells  were washed  and  resuspended  at 2  x 
l(P/ml in RPMI 1640 (Irvine .Scientific) with the addition of an- 
tibioties, glutamine, 50/~M 2-ME, and 10% heat-inactivated FCS. 
2  x  10  s cells were  added  to each well  of a round-bottomed 
96-well plate in a total volume of 100/.d. A further 100/~1 of medium 
was then added containing  one of a number of antibodies: F(ab')z 
fragments of affinity-purified, spedeS-SlXXfific  goat anti-human IgM, 
goat anti-mouse Ig, or goat anti-mouse IgM 0ackson Immuno- 
research); sohble or aggregated human IgG (Cappd, Durham, NC). 
Other e~periments utilized LPS from Salmonella minnesota (Sigma 
Chemical  Co.). Soluble human IgG was prepared by pelleting a 
10-20 mg/ml solution of human IgG at 160,000 g for 1-2 h; the 
upper 25% was then removed and used in the assays. Aggregated 
human IgG was prepared by heating  a 10-20 mg/ml solution at 
63~  for 1 h followed by cooling on ice for 2 h. All tests were 
performed  in triplicate. Proliferation was measured on day 3 by 
Les Kappa  Light Chain gene 
the addition of 1 ~Ci of [3I-I]Tdr per well and the assay terminated 
18 h hter. 
Results 
Establishment of Human RF Tmnsgenic Mice  Transgenic 
mice were created that express the heavy and fight chain genes 
coding for the Les human IgM RF. These genes had been 
isolated from RF-expressing B-CLL ceils  (19-21).  The VK 
gene is derived from Vk328 (19-20), a conserved Vk3 sub- 
group gene that often encodes fight chains of human autoan- 
tibodies. The Vh gene is most likely derived from Vh4.21 
(21, 22). The products of these genes are readily detectable 
in the mouse background by use of human  Ig-specific re- 
agents;  in addition,  the K light  chain is recognized by the 
routine antiidiotypic antibody 6B6.6 (20, 23), whereas the 
heavy chain is detected by the monoclonal antiidiotype 9(34 
(24). The constructs used for microinjection  are shown in 
Fig. 1. The heavy chain gene was modified by the insertion 
of the mouse heavy chain enhancer at the HindIII site just 
5' of the switch region. Of seven founder lines that had human 
IgM RF in their serum, two (AB8 and AB29) were found 
to simultaneously express human IgM and human K on the 
B cell surface.  These latter lines were selected for further ex- 
perimentation. 
B  Cell-specific Expression of Human  IgM RE  Approxi- 
matdy 15% (range, 13-16%) of AB8 splenic B cells and 70% 
(range, 46-90%) of AB29 splenic B cells express human RF 
on the cell surface.  Fig. 2 shows a representative dual-color 
FACS  |  analysis  of spleen ceils  from AB29 mice.  The two 
transgenes were coordinately expressed on the surface of B 
ceils.  There was no coexpression with T  ceU markers such 
as CD4 (or CDS; data not shown). There appears to be com- 
plete aUdic exnhsion between the transgenic protein and mouse 
IgG and IgD in B ceils.  In most experiments, human IgM 
RF-positive ceils expressed neither mouse IgM nor g (as shown 
in Fig. 2). However, occasionally in some experiments, it ap- 
peared that there may be a small proportion (<5%) of calls 
that express very low levels of murine IgM and K in conjunc- 
tion with human IgM RF. Table 1 shows the phenotype of 
AB29 spleen cells. Results are expressed as mean percentage 
and range of the total splenic mononuclear call population 
that expresses each antigen.  Seven mice are included in each 
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Figure  2.  FACS  |  analysis  of 
AB29 spleen cells. Note the anti- 
mouse  IgG  reagent  crossreacts 
weakly with other routine Igs. Con- 
sequendy, the percentages shown 
represent more than just mouse sur- 
face IgG-positive cells. 
group unless stated otherwise. AB29 transgenic mice have 
80% of normal B cell levels; consequently there is a compen- 
satory increase in the percentage of total cells that express 
T cdlmarkers. Cells expressing mouse Ig are reduced to 15% 
of the levels of control littermates, due to allelic exclusion 
by human IgM RF. 
Fig. 3 shows staining of transgenic spleen for human and 
mouse Igs. RF-positive cells show characteristic  staining in 
the primary B cell follicles of the white pulp (,4) and in the 
mantle zones of secondary follicles (B). These are areas where 
small B lymphocytes are characteristically located. There are 
few R.F-positive cells within the germinal centers of secondary 
follicles, which are usually the sites of antigen-induced B cell 
expansion. The localization of B cells expressing the trans- 
gene is consistent with a lack of antigen-induced expansion 
of human IgM RF in the mice.  In transgenic spleen  the 
number of mouse Ig-bearing cells is reduced compared with 
normal spleen, as shown in Fig. 3, C and D. The remaining 
mouse Ig-positive cells are located within the foUides and 
the marginal zone of the white pulp. 
High Levels of  Su~ace lgM RF Expression Are Not Accompa- 
nied by High Levels of  Secretion.  AB8 and AB29 mice secreted 
an average of 2 #g/ml (n  --  21) and 12.9 #g/ml (n  =  36) 
human RF at 4-5 wk of age corresponding to -1 and 6% 
of total serum IgM. Thus, although 70% of the B cells from 
AB29 mice express human IgM on their cell surface, this 
human Ig comprises a small percentage of total serum Ig levels. 
This is not surprising, as these mice are not exposed to human 
IgG and so the KF B cells lack antigenic selection. However, 
injection of the mice with 50/~g/ml aggregated human IgG 
112  Transgenic Mice Expressing a Human lgM Rheumatoid Factor Autoantibody Figure 3.  Immunohistochemical  analysis of spleen sections from AB29 mice and control littermates.  (,4 and B) High-power view (x400) of AB29 
spleen stained for human IgM. (C) High-power view of control spleen stained for mouse Ig. (D) High-power view of AB29 spleen stained for mouse 
Ig. I~  a primary B cell follicle; T, the periarteriolar  lymphatic  sheath (T cell area). M, the mantle zone of the secondary follicle; GC, the germinal 
center.  The marginal  zone of the white pulp is indicated by arrows. 
Table  1.  Phenotype  of AB29 Spleen ceils 
Percentage  of total  cells 
AB29 mice  Control littermates 
Cell surface marker  (n  =  7)  (n  =  7) 
B cells  55.4 (43-67)  69.6 (57-78) 
Human IgM  39.1 (28-55)  0.0 
Human g  40.6 (26-53)  0.0 
Mouse IgM  10.7 (5-24)  60.6 (46-78) 
Mouse ~r  10.3 (6-22)"  64.7 (52-74) 
Mouse IgD  4.8 (3-10)  ~  52.2 (39-64)" 
T cells (CD4+CDS)  35.0 (24-43)*  20.5 (20-29)* 
The results show the mean percentages of total splenic mononuclear cens 
that  express each antigen;  the ranges  are shown in parentheses. 
"n-6. 
*n-5. 
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emulsified in CFA followed by boosting 2 wk later with ag- 
gregated human IgG in IFA did not increase serum levels 
of human IgM although a mouse anti-human IgG response 
was induced (data not shown). We concluded that, although 
unlikely, the presence  of low levels of soluble IgM ~  in 
the circulation may interfere with human IgG binding to the 
tLF B cell surface. Consequently, to avoid the problem of 
competing soluble antibody, we stimulated freshly obtained 
spleen cells in vitro with bacterial  LPS and then analyzed 
the culture supernatants 6 d hter for their content of human 
and mouse Ig. LPS (20/~g/ml) induced much higher levels 
of secretion of mouse Ig (mean of AB8, 207/~g/ml; mean 
of AB29, 356/zg/ml; mean of nontransgenic littermate, 366 
/zg/ml) than of human IgM (mean of AB8, 0.2/~g/ml; mean 
of AB29, 0.4/zg/ml), despite, in the case of AB29 mice, a 
higher percentage of cells expressing human Ig. In addition, 
stimulation of the transgenic splenocytes in vitro with ag- 
gregated human IgG in the presence of T  cell replacement 
factors derived from Con A-stimulated mouse lymphocytes 
did not augment human IgM secretion (data  not shown). These data would suggest that the RF-positive B ceils that 
have differentiated in the transgenic environment normally 
release only small amounts of IgM RF and that high levels 
of secretion can not be readily induced. 
Splenocytes  from Transgenic  Mice Are Immunocompetent.  In 
AB29 mice, 70% of splenic B cells express human IgM. How- 
ever, the mice do not appear to be immunocompromised  by 
the reduction in mouse Ig-expressing B cells, as demonstrated 
by apparently normal levels of mouse Ig compared with their 
nontransgenic littermates (data not shown). In addition, the 
transgenic mice generated high titers of mouse antibodies to 
either keyhole limpet hemocyanin, or to other human IgM 
paraproteins.  Thus, AB8 and AB29 mice would appear  to 
be a useful system in which to examine the function of RF- 
expressing cells in the relative absence of secreted antibody 
or antigen, as a substantial proportion of cells express the 
human Ig in a B cell-specific manner and with a normal ana- 
tomical distribution, but this does not, at least superficially, 
interfere with endogenous immune competence. 
Transgenic B  Cells Can Be Signaled through Their Human 
IgM Surface Receptor.  The human IgM 1LF on the cell sur- 
face of transgenic spleen cells can act as a receptor in much 
the same was as endogenous  mouse Ig, as shown by the ability 
of anti-human IgM to stimulate the cells to proliferate (Table 
2). Fig. 4 shows the results of a representative  experiment 
in which AB29 splenocytes were stimulated in vitro with 
human IgG as an antigen. Pulsing spleen ceils for 1 h on 
ice with 20 #g/ml soluble human IgG, followed by washing 
away excess, induced little proliferation of either transgenic 
or nontransgenic spleen cells. However,  pulsing with ag- 
gregated human IgG induced proliferation of transgenic, but 
not control spleen cells. The results show that the aggrega- 
Table  2.  Proliferation  of Spleen  Cells in response to Anti-Ig 
Stimulation 
[SH]Thymidine incorporation in response to: 
Spleen cell  Anti-human  Anti-mouse 
donor  Mouse  IgM  Ig  LPS 
c~m 
AB8  1  68,494  78,055  94,089 
AB8  2  67,936  90,154  110,456 
AB29  1  78,046  4,441  126,476 
AB29  2  114,010  4,717  138,056 
Non-Tg  1  2,004  115,754  101,699 
Non-Tg  2  664  117,893  132,145 
2  x  10s spleen cells from pairs of AB8, AB29 mice, and nontransgenic 
littermates,  age 11-17 wk, were cultured in the presence of 20/Lg/ml 
of F(ab)2 fragments  of goat anti-human IgM or goat anti-mouse Ig 
(affinity absorbed for crossreactivity with other species) or LPS (Escherichia 
coh~. Results are expressed as means of triplicates.  Background cpm in 
the presence of medium alone  have been subtracted  from  all values. 
pH]Thymidine incorporation was measured after 3 d. The results shown 
here are from  a representative experiment. 
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Figure 4.  Proliferation of AB29 transgenic spleen cells in response to 
stimulation by human IgG. 2  ￿  10  s spleen cells were cultured in the pres- 
ence of LPS (g  minnesota) at  10 /~g/ml,  affinity-purified F(ab')2 goat 
anti-human IgM (species specific) at 10 #g/ml, affinity-purified F(ab')2 
goat anti-mouse Ig (species specific) at 10 I~g/ml, or were incubated with 
either soluble or heat-aggregated human IgG at 20/~g/ml for 1-2 h at 
4~  washed, and then cultured in medium. Results are expressed as means 
of triplicates. Background proliferation in the presence of medium alone 
has been subtracted from all values. [3H]Thymidine incorporation  was 
measured after 3 d.  TG  +, AB29 mouse;  TG-, control littermate. 
tion of the antigen was able to achieve a sufficient degree 
of crosslinkin~ to stimulate proliferation of transgenic B ceUs. 
Transgenic RF B Cells Are Highly E/~cient APC for Immune 
Complexes,  Lymph  node cells from C57/B16 mice immunized 
10 d previously with 100 #g tetanus toxoid (TT) in CFA 
were used as a source of TT-speeific Th cells. Spleen cells from 
transgenic mice or nontransgenic littermates were used as 
APCs. These cells received 1,000 rad to inhibit their prolifer- 
ation, while preserving their ability to process and present 
antigen (25). Immune complexes were preformed in the cul- 
ture wells by incubating TT with human IgG anti-TT in 
varying proportions for 2 h at 37~  Lymph node Th and 
APC were then added and proliferation of Th measured at 
days 3-4. As shown in Fig.  5 A, AB29 spleen and control 
spleen were equally able to present soluble TT. However, when 
increasing amounts of human IgG anti-TT were titrated against 
a constant amount (10 ng/ml) of TT in order to form im- 
mune complexes,  the ability of AB29 spleen to present an- 
tigen was substantially enhanced, whereas that of control 
spleen was unchanged (Fig. 5 B). The spleen cell population 
containing 1LF-expressing B cells was able to process and 
present 500-1,000-fold lower concentrations of antigen when 
that antigen was present in the form of an immune complex, 
compared with soluble antigen alone. As little as 10 ng/ml 
anti-TT antibody, in the presence of antigen, induced vig- 
orous T cell proliferation,  as determined by [3H]Tdr uptake. 
As spleen cells from nontransgenic littermates showed no such 
enhanced ability to present small amounts of immune com- 
plexed antigen to T cells, we conclude that the enhanced an- 
tigen presentation capacity of the AB29 spleen was due to 
the specificity of its Ig receptor. 
High Levels of Secretion of lgM RF Can Be Induced.  The 
lack of secretion of human IgM RF by B cells in people could 
be the result of continuous exposure to high concentrations 
of monomeric IgG. However, the inefficient secretion oflgM 
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Figure 5.  Comparison  of the ability of spleen cells from AB29 mice 
and control littermates to present TT-human IgG routine complexes to 
TT-specific T cells. (A) Proliferation of TT-specitic T cells to increasing 
concentration of TT presented  by spleen  cells  from AB29  mice  (open  symbol) 
and control littermates (filled  symbol). (B) Proliferation of TT-specific  T 
cells to preformed immune complexes  composed  of 10 ng/ml TT and in- 
creasing concentrations of human IgG anti-TT presented by spleen cells 
from AB29 mice (open symbol) and control littermates (filled symbol). 
1LF by the transgenic B cells cannot be attributed to toler- 
ance caused by a weak crossreactivity with routine IgG. The 
IgM RF, Les, did not show any greater binding to an ELISA 
plate coated with aggregated mouse IgG than other antigens 
such as TT or even an uncoated plate. This was in spite of 
being tested at concentrations as high as 40/~g/ml, this level 
being approximately three times higher than that usually seen 
in AB29 mouse serum.  To determine if the low secretion 
of IgM RF represented an irreversible state, the spleen cells 
from the AB29 transgenic mice were fused with NSO my- 
eloma cells. The mean human IgM level secreted in vitro by 
the resultant hybrids was 40 #g/ml (n  =  4), a level indistin- 
guishable from that typically secreted by mouse Ig-producing 
hybridomas.  These results indicate that  IgM RF could be 
secreted at high levels if appropriate cofactors were provided. 
To examine whether breeding the transgene onto strains 
of mice prone to autoimmunity could result in increased IgM 
RF production in vivo, the AB8 mice were bred onto the 
MRL/Ipr  background  for  two  generations.  The  Ipr/lpr 
(homozygous) mice were identified by the development of 
lymphoid eulargement by week 16.  Table 3 shows that  by 
16 wk, secretion of human IgM RF increased >200-fold in 
the serum of AB8 mice that are homozygous for the Ipr gene, 
reaching a mean serum level of 364/~g/ml.  In contrast, het- 
erozygous animals maintain low levels of secretion. This sug- 
gests that recessive genetic factors can lead to high-level secre- 
tion  of the human  IgM  RF autoantibody transgenes. 
Discussion 
In this report we describe two lines of transgenic  mice, 
AB8 and AB29, that produce a human IgM RF that is specific 
for human IgG. The transgene-expressing B cells from these 
mice share many properties with RF-expressing B cells  in 
Table  3.  Serum Levels of Huraan IgM RF and Mouse Ig in 
AB8 Mice Backcrossed with MRL/I~ Mice for Two Generations 
Mice  Human IgM RF  Mouse Ig 
~g/mI  rag/ral 
TG + Ipr/Ipr (n  =  7)  364  +  240  23.3  •  2.6 
(0.2-1,768)  (15.4-34.1) 
TG + Ipr/-  (n  =  6)  1.6  +  0.5  3.7  +  1.0 
(0.6-3.8)  (1.1  +  8.4) 
TG-  l~/lpr (n  =  6)  0.0  34.4  •  13.0 
(0.0)  (8.3-88.7) 
TG-  Ipr/-  (n  =  10)  0.0  4.4  •  0.5 
(0.0)  (1.8-6.7) 
Serum Ig  levels were measured at  week 16  and  are  expressed as 
mean _+ SE. The range for each group is in parentheses. TG, IgM RF 
transgene. 
normal humans.  The B cells expressing the IgM RF in the 
Les transgenic mice make up a substantial proportion of the 
total B cell pool. In AB8 mice 13-16% of splenic B cells ex- 
press human IgM and r, and in AB29 mice between 46 and 
90% of splenic B cells express transgenic Igs. Such high per- 
centages of RF-expressing B cells exist in these mice in the 
apparent absence of antigenic selection. Human IgM RF does 
not bind to mouse IgG (as detectable by ELISA) and the high 
degree of allelic  exclusion seen between human and mouse 
Igs means that we cannot ascribe expansion to coexpression 
and stimulation  of mouse Ig. 
Analysis of immunohistological sections of the transgenic 
mouse spleens showed that RF-expressing B cells home to 
primary B cell follicles  and the mantle  zones of secondary 
follicles and apparently survive in the absence of self-antigen. 
It seems either that these cells do not require continued an- 
tigen stimulation for long-term survival,  or that they are con- 
tinuously being replenished by new precursors from the bone 
marrow. 
Expression of the human IgM RF apparently does not sub- 
stantially interfere with endogenous immune function as de- 
termined by assays that  measure mouse Ig serum levels or 
antibody responses to foreign antigens.  Furthermore, although 
a large percentage of B cells express surface human RF, the 
proportions of human-to-mouse Ig in such animals are low, 
comprising  "~1 or 6%  of serum  IgM in AB8 and AB29, 
respectively. The discordance in the cellular ratios of RF trans- 
gene-~pressing cells and serum IgM RF has striking parallels 
with that observed in human physiologic situations (5). In 
the transgenic mice, this is not surprising,  as the transgene 
RF B cells exist in the absence of their target antigen and, 
therefore,  presumably are not activated.  This hypothesis is 
supported by the relative paucity of RF transgene-expressing 
B cells in germinal centers of secondary lymphoid follicles 
arguing against their recruitment into secondary immune re- 
sponses.  In addition,  IgM RF-expressing B cells are indis- 
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determined by light scatter (data not shown). However, it 
is surprising, that after exposure in vitro to a polyclonal B 
cell mitogen such as LPS, the B cells expressing mouse Ig 
synthesize 20 times more Ig in AB8 mice, or 100-1,000 times 
more Ig in AB29 mice, than cells expressing the RF trans- 
genes.  The RF transgene-expressing B cells, however, can 
be stimulated to proliferate  in vitro by aggregated human 
IgG, as well as by bivalent anti-human IgM antibody. Thus, 
such tLF transgene-expressing B cells can be signaled through 
their human IgM receptor,  but are not readily induced to 
differentiate into antibody-secreting plasma cells by polyclonal 
B cell activators. 
A number of investigators have shown B ceUs to be highly 
effective APC, using their Ig receptor to capture very small 
amounts of their specific antigen (8-12). IgM EF-expressing 
B cells may likewise have a role as a universal APC for immune- 
complexed antigen. For such a function it would be advanta- 
geous to the organism to have large numbers of cells expressing 
cell surface human IgM RF, but with little secreted ILF, in- 
sofar as secreted antibody would compete for immune com- 
plex binding and presentation. Our experiments show that 
transgenic IkP B cells function as an excellent source of APC 
for antigens such as TT present in the form of immune com- 
plexes with human IgG. The IkF B cells are fully able to 
process and present antigen and ddiver the necessary second 
signals to normal TT-primed Th cells. It has previously been 
shown that tkF-expressing EBV-transformed B cell lines can 
act similarly in vitro (13), but this is the first demonstration 
of antigen presentation by a population of lkF-expressing B 
cells that are untransformed, presumably resting, and conse- 
quently more closely represent the physiological state of the 
IkF-expressing  B calls present in the mantle zones of lym- 
phoid tissues. 
Lymphoid tissues contain several classes of APC, including 
dendritic cells, macrophages, and B lymphocytes. Immune- 
complex~l antigens internalized by the Fc3dlI (CD16) receptor 
on macrophages are et~ciently presented (26).  In contrast, 
antigens targeted to the FCqdI (CDw32) receptor on B lym- 
phocytes are not presented, and may inhibit B cell activation 
(27-31).  However, surface RF also may be considered an Fc- 
binding molecule that can facilitate antigen presentation of 
immune complexes. Upon secondary immunization, antigen 
arrives in the sinuses of draining lymph nodes in the form 
of immune complexes (32). At very low antigen concentra- 
tions, uptake by conventional APCs may be suboptimal, and 
the presence of antigen-IgG immune complexes may lead to 
feedback inhibition of presentation by antigen-specific B ceils 
(29, 30). Under these conditions, RF-expressing B cells may 
play a major role in antigen presentation and activation of 
the antigen-reactive T  cells required for specific B cell ex- 
pansion. 
Normally, serum levds of IgM RF are low; however, under 
certain circumstances,  secretion of RF can be dramatically 
increased. Fusion of RF-positive B cells with mydoma ceUs 
to produce hybridomas rescues Ig secretion in both humans 
(5) and, as shown here, in the RF transgenic mice. Hybrid- 
omas derived from AB29 spleen cells secrete human IgM at 
approximatdy the same levels as mouse Ig-producing hybrid- 
omas. Patients with R.A,  Sjrgren's syndrome, and mixed 
cryoglobulinemia also secrete high levels of IgM IkFs in the 
absence of known antigenic stimulation (3). Similarly, we 
found that breeding transgenic mice onto the autoimmune 
MRL/Ipr background led to very high levels of human IgM 
secretion: a >200-fold increase compared with normal levels. 
We interpret this result to show that the RF-expressing trans- 
genie B cells can differentiate into plasma cells that are fully 
competent for antibody secretion. Mice that are homozygous 
for the Ipr mutation have defective expression of the Fas sur- 
face antigen, which mediates apoptosis in immature T calls 
(33). The expression of the autoimmune phenotype in the 
lpr homozygous mice requires  B as well as T cells (34). In 
the lkF transgenic mice, high levels of autoantibody secre- 
tion may be secondary to the effects of the MRL/Ipr back- 
ground on B cell survival  or differentiation. 
The ILF transgene-expressing B cells analyzed in this re- 
port show striking similarities to their normal human coun- 
terparts, in spite of development in a milieu where they have 
no apparent ligand. Use of transgenic mice expressing rear- 
ranged antigen receptor genes has contributed significantly 
to our understanding of the fate of autoreactive cells in the 
presence of antigen. It appears that these cells may either be 
anergized, be deleted, or persist unchanged in the circulation 
(35-43). The factors that deride these difftrent outcomes have 
not been fully ducidated, but seem to be a function of anti- 
body binding affinity, whether the antigen is soluble or bound 
to a cell surface, and antigen concentration. Experiments are 
in progress to determine the effect upon tLF B cell function 
of development in an environment containing high levels of 
human IgG. 
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